Your browser doesn't support javascript.
loading
Drug-related problems and risk factors related to unplanned hospital readmission among cancer patients in Belgium.
Koubaity, Majda; Lechon, Anne-Sophie; Amighi, Karim; Van Nuffelen, Marc; Moreau, Michel; Meert, Anne-Pascale; De Vriese, Carine.
Afiliação
  • Koubaity M; Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, CP 205/07, Access 2, Campus de la Plaine, Building BC, 1050, Brussels, Belgium.
  • Lechon AS; Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, CP 205/07, Access 2, Campus de la Plaine, Building BC, 1050, Brussels, Belgium.
  • Amighi K; Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, CP 205/07, Access 2, Campus de la Plaine, Building BC, 1050, Brussels, Belgium.
  • Van Nuffelen M; Department of Intensive Care and Emergency, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium.
  • Moreau M; Department of Information Management Unit (UGI), Institute Jules Bordet, Brussels, Belgium.
  • Meert AP; Department of Internal Medicine, Intensive Care Unit and Oncology Emergency, Institute Jules Bordet, Université libre de Bruxelles, Brussels, Belgium.
  • De Vriese C; Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, CP 205/07, Access 2, Campus de la Plaine, Building BC, 1050, Brussels, Belgium. cdevries@ulb.ac.be.
Support Care Cancer ; 29(7): 3911-3919, 2021 Jul.
Article em En | MEDLINE | ID: mdl-33389085
ABSTRACT

INTRODUCTION:

There are about 60,000 diagnoses of cancer per year in Belgium. After hospital care, about 12-13% of cancer patients are readmitted within 30 days after discharge. These readmissions are partly related to drug-related problems (DRP), such as interactions or adverse drug effects (ADE).

OBJECTIVES:

The aim of this study is to quantify and to classify DRP readmissions within 30 days for cancer patients and to highlight risk factors potentially correlated to readmissions.

METHODS:

This study is a 6-month observational retrospective study in two care facilities in Brussels an academic general hospital and an academic oncology center. Patients readmitted within 30 days after their last hospital care for a potential DRP were included. Patient files were evaluated with an intermediate medication review that included interactions analysis (Lexicomp®). The probability of DRP readmission was assessed using the World Health Organization's Uppsala Monitoring Centre (WHO-UMC) system.

RESULTS:

The final population included 299 patients; among them, 123 (41.1%) were readmitted due to DRP (certain DRP (4.9%), probable DRP (49.6%), and possible DRP (45.5%)). Risks factors linked to these DRP were a low Charlson Comorbidity Index, polypharmacy, the kind of hospital, and some chemotherapies (platinum preparations). Among all readmitted patients, the D-type interactions were the most common (44.8%), which suggest a possible therapy modification. However, around 10% of interactions were X-type (drug combination to avoid).

CONCLUSION:

Almost 10% of patient readmitted within 30 days were potentially related to a DRP, most of them from adverse drug effects. Four risk factors (low Charlson Comorbidity Index, polypharmacy, the hospital, and some chemotherapies) were highlighted to prevent these readmissions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Readmissão do Paciente / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Neoplasias Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Readmissão do Paciente / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Neoplasias Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article